SUN CITY WEST, Ariz.–(BUSINESS WIRE)–The National Animal Supplement Council (NASC) today announced that Frontiers in Veterinary Science (Front. Vet. Sci.) has published results from the first-of-its-kind peer-reviewed safety study of cannabidiol products in healthy dogs. In the study, different cannabinoids were well tolerated in healthy male and female dogs when dosed for 90 consecutive days with a 14-day recovery period. Based on the results of this study, other published studies, and data from extensive post-market surveillance, hemp-derived cannabinoids are well tolerated in healthy dogs at a dose of 5mg/kg of body weight per day and do not pose significant risk to dogs in long-term use.
“These data demonstrate that different cannabidiols are safe for long-term use in healthy dogs when given at the dose studied,” said Bill Bookout, NASC President. “With safety studies, no matter how well controlled or meticulously defined, it is impossible to account for everything that can occur when a product is commercialized. That is why this safety study includes not only data from a well-designed study protocol, but also 10 years of post-market surveillance data from the NASC Adverse Event Reporting Database (NAERS®), which is the most advanced monitoring system in the world for these types of products given to companion animals. No other study that we are aware of is as comprehensive and includes both data sets.”
In the pivotal study, 32 healthy beagle dogs (16 males and 16 females) were randomized into four treatment groups and treated with either medium chain triglyceride oil as the control (placebo) or one of the following: broad spectrum cannabidiol (CBD), broad spectrum cannabidiol with cannabigerol (CBD + CBG), or broad spectrum cannabidiol with cannabidiolic acid (CBD + CBDA), at a dose of 5 milligrams total cannabinoids per kilogram of body weight per day. All animals completed the study. Study results show that CBD, CBD + CBG and CBD + CBDA at the ratios and doses utilized were well tolerated over the duration of the study period when healthy male and female beagles were dosed for 90 consecutive days.
The full study with references and supplementary material can be viewed here.
“There are many people to thank for their support in the completion of this study, however, it is the contributions of the NASC Board of Directors and NASC members, along with retailers and veterinarians who helped propel this landmark study forward,” Bookout said. “Special thanks go to study co-authors Margitta Dziwenka, Kaiti Valm, and Jennifer Kovacs-Nolan for their invaluable assistance with what has been a lengthy, but extremely rewarding process. Thanks also to Joseph J. Wakshlag, DVM, PhD, of the Cornell College of Veterinary Medicine for his support and encouragement along the way as we completed this instrumental study.”
About the National Animal Supplement Council
The National Animal Supplement Council is a nonprofit trade association whose mission is to promote the health and well-being of companion animals and horses given animal health supplements by their owners and to protect and enhance the animal health supplement industry. The NASC began in 2001 as a grassroots effort with 18 dedicated founding member companies and today is the leading voice for the industry, representing nearly 300 companies that supply animal health and nutritional supplements, as well as over 140 companies that supply raw materials, manufacturing, analytical laboratory testing and other professional services to NASC members. The NASC Quality Program, including its audit verification, provides a roadmap to quality and consistency for NASC members and is widely recognized as the Gold Standard for the industry. Look for the yellow NASC Quality Seal on supplements for dogs, cats, and horses to know you are buying from a responsible supplier that has passed a comprehensive third-party audit and maintains ongoing compliance with rigorous NASC quality requirements. Learn more at animalsupplements.org.
Contacts
Bill Bookout, President
National Animal Supplement Council
[email protected] | 760-751-3360 x101